Choueiri, T. K., Pal, S. K., McKay, R. R., Suarez, C., Haanen, J., Warad, D., Negro, C., Eisen, M. J., Foster, P. G., Powles, T. (2026). PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps4636